Business Description
Bioporto A/S
ISIN : DK0011048619
Description
Bioporto A/S is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.94 | |||||
| Equity-to-Asset | 0.58 | |||||
| Debt-to-Equity | 0.16 | |||||
| Debt-to-EBITDA | -0.12 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 9.82 | |||||
| Beneish M-Score | -1.9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -7.6 | |||||
| 3-Year EBITDA Growth Rate | 17.7 | |||||
| 3-Year EPS without NRI Growth Rate | 18.4 | |||||
| 3-Year FCF Growth Rate | 3.8 | |||||
| 3-Year Book Growth Rate | -24.3 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 84.38 | |||||
| 9-Day RSI | 67.67 | |||||
| 14-Day RSI | 58.51 | |||||
| 6-1 Month Momentum % | -28.66 | |||||
| 12-1 Month Momentum % | 40.91 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.48 | |||||
| Quick Ratio | 2.36 | |||||
| Cash Ratio | 1.76 | |||||
| Days Inventory | 88.51 | |||||
| Days Sales Outstanding | 43.8 | |||||
| Days Payable | 189.25 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -11.1 | |||||
| Shareholder Yield % | -4.32 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 68.08 | |||||
| Operating Margin % | -178.88 | |||||
| Net Margin % | -166.23 | |||||
| FCF Margin % | -153.79 | |||||
| ROE % | -87.12 | |||||
| ROA % | -58.95 | |||||
| ROIC % | -199.05 | |||||
| ROC (Joel Greenblatt) % | -2101.37 | |||||
| ROCE % | -86.96 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 23.64 | |||||
| PB Ratio | 18.91 | |||||
| Price-to-Tangible-Book | 14.4 | |||||
| EV-to-EBIT | -14.71 | |||||
| EV-to-EBITDA | -15.4 | |||||
| EV-to-Revenue | 26.4 | |||||
| EV-to-Forward-Revenue | 21.05 | |||||
| EV-to-FCF | -17.16 | |||||
| Price-to-Median-PS-Value | 1.31 | |||||
| Price-to-Net-Current-Asset-Value | 28.8 | |||||
| Price-to-Net-Cash | 28.8 | |||||
| Earnings Yield (Greenblatt) % | -6.8 | |||||
| FCF Yield % | -5.58 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers